Watson’s Generic Lovenox Launches At Risk; Will Sanofi’s Authorized Generic Follow?
This article was originally published in The Pink Sheet Daily
An appeals court lifted a preliminary injunction that blocked Amphastar and U.S. marketing partner Watson from selling their generic version of Sanofi’s blood thinner. Watson is to launch immediately in the U.S.
You may also be interested in...
Attorneys say Sarepta did not have an obligation to report its appeal, particularly since winning a formal dispute filing with the US FDA is a long shot.
The apparently first-ever FDA press release for an advertising warning letter underscores importance of opioid issues – and the agency’s changing approach to media relations in general. FDA objects to Alkermes journal ad that excludes risk information about its opioid dependence treatment drug.